NCT03065556已完成2 期
A Double-Blind, Randomized, Multicenter, Vehicle-Controlled, Parallel Group Study to Determine the Efficacy and Safety of 188-0551 in Subjects With Plaque Psoriasis Receiving Up To Four Weeks of Twice-Daily Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 89
- 试验地点
- 1
- 主要终点
- Proportion of subjects rated a treatment success based on the Investigator's Global Assessment (IGA)
研究概览
简要总结
This Phase 2 study (Study 203) has been designed to determine and compare the efficacy and safety of 188-0551 Solution and Vehicle Solution applied twice daily for up to four weeks in subjects with plaque psoriasis. Subjects will be instructed to apply the test article (188-0551 Solution or Vehicle Solution) to all psoriasis plaques within the designated Treatment Area twice daily for four weeks (Study Day 29), unless the investigator verifies the subject's psoriasis has cleared at Day 15, then test article application will be for 2 weeks (Study Day 15).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject is male or non-pregnant female and is at least 18 years of age.
- •Subject has provided written informed consent.
- •Subject is willing and able to apply the test article(s) as directed.
- •Subject has a clinical diagnosis of stable plaque psoriasis.
- •Subject has an Investigator's Global Assessment (IGA) score of at least three (3 = moderate) at the Baseline Visit.
- •Females must be post-menopausal, surgically sterile or use an effective method of birth control, with a negative urine pregnancy test (UPT) at the Baseline Visit.
排除标准
- •Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.
- •Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.
- •Subject has a physical condition which, in the investigator's opinion, might impair evaluation of plaque psoriasis.
- •Subject has used any phototherapy (including laser), photo-chemotherapy or other forms of photo based therapy for the treatment of their psoriasis within 30 days prior to the Baseline Visit.
- •Subject has used any systemic tofacitinib, apremilast, methotrexate, retinoids, systemic corticosteroids [including intralesional, intra-articular, and intramuscular corticosteroids], cyclosporine or analogous products within 90 days prior to the Baseline Visit.
- •Subject has used any systemic anti-inflammatory biologic therapy.
- •Subject had prolonged exposure to natural or artificial sources of ultraviolet radiation within 30 days prior to the Baseline Visit or is intending to have such exposure during the study which in the opinion of the investigator is thought to modify the subject's disease.
- •Subject has used topical body (excluding the scalp) psoriasis therapy (including coal tar, anthralin, steroids, retinoids and vitamin D analogs) within 14 days prior to the Baseline Visit.
- •Subject has used emollients/moisturizers on areas to be treated within four hours prior to clinical evaluation at the Baseline Visit.
- •Subject is currently using lithium or Plaquenil (hydroxychloroquine).
- •Subject is currently using a beta-blocking medication (e.g., propranolol) or angiotensin converting enzyme (ACE) inhibitor at a dose that has not been stabilized, in the opinion of the investigator.
- •Subject has a history of sensitivity to corticosteroids or any of the ingredients in the test articles.
- •Subject is pregnant, lactating, or is planning to become pregnant during the study.
- •Subject is currently enrolled in an investigational drug or device study.
- •Subject has used an investigational drug or investigational device treatment within 30 days prior to the Baseline Visit.
- •Subject has been previously enrolled in this study and treated with a test article.
研究组 & 干预措施
188-0551 Solution
Experimental
188-0551 Solution applied topically twice daily
干预措施: 188-0551 Solution (Drug)
Vehicle Solution
Placebo Comparator
Vehicle Solution applied topically twice daily
干预措施: Vehicle Solution (Drug)
结局指标
主要结局
Proportion of subjects rated a treatment success based on the Investigator's Global Assessment (IGA)
时间窗: End of Study (Day 15 or 29)
The primary efficacy endpoint will be the proportion of subjects with IGA treatment success at EOS where EOS is the subject's last completed post-Baseline visit (Day 15 or 29).
次要结局
- Proportion of subjects rated a treatment success for each of the clinical signs of psoriasis (scaling, erythema and plaque elevation)(End of Study (Day 15 or 29))
- Change from Baseline in pruritus score(End of Study (Day 15 or 29))
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy Study of DUR-928 Topical Solution in Subjects With Plaque PsoriasisPlaque PsoriasisNCT03837743Durect25
已完成
2 期
A Study of VBP-245 in Pediatric Patients With Molluscum ContagiosumMolluscum ContagiosumNCT03077750Veloce BioPharma LLC110
已完成
3 期
A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque PsoriasisPlaque PsoriasisNCT03759197Therapeutics, Inc.206
已完成
2 期
A Phase 2 Efficacy Study of CLS003 ICVT in Subjects With Cutaneous Warts.Cutaneous WartsNCT02333643Maruho Co., Ltd.81
已完成
3 期
Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis (307)Plaque PsoriasisNCT03731052Therapeutics, Inc.217